BeyondSpring (BYSI) Stock Analysis & Winston Score

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing cancer drugs. Its lead drug candidate is plinabulin, which is designed to help cancer patients avoid dangerous drops in white blood cell counts caused by chemotherapy — a condition called chemotherapy-induced neutropenia. The company targets oncology markets and works primarily with hospitals and cancer treatment centers. BeyondSpring does not yet generate meaningful revenue, which explains its zero gross margin and deeply negative returns. It is headquartered in New York but conducts much of its research and operations through a subsidiary in China, giving it a dual US-China presence. The company has pursued regulatory approval in both the United States and China, but plinabulin has faced setbacks including an FDA rejection, which remains the central risk — without an approved product, the company must continue spending cash to fund trials while relying on external financing to survive.